Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel
NASDAQ:VIVS

VivoSim Labs Q1 2026 Earnings Report

VivoSim Labs logo
$1.19 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.16 -0.03 (-2.44%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

VivoSim Labs EPS Results

Actual EPS
-$1.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

VivoSim Labs Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

VivoSim Labs Announcement Details

Quarter
Q1 2026
Date
8/12/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

VivoSim Labs Earnings Headlines

VivoSim Labs Inc VIVS
May 17, 2026  |  morningstar.comM
VivoSim Labs Inc
May 14, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/VIVS
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
June 9 at 1:00 AM  |  Brownstone Research (Ad)
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
April 28, 2026  |  financialpost.comF
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/28/3282625/37000/en/vivosim-platform-predicts-gastrointestinal-toxicity-diarrhea-in-an-ai-model-trained-on-human-intestinal-model-results-without-animal-testing.html
VivoSim Labs, Inc. Common Stock (VIVS) Real Time
April 7, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/vivs/real-time
See More VivoSim Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like VivoSim Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VivoSim Labs and other key companies, straight to your email.

About VivoSim Labs

VivoSim Labs (NASDAQ:VIVS) (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology. These platforms support a range of applications from high-throughput screening and mechanism-of-action studies to personalized medicine initiatives, allowing pharmaceutical and biotechnology customers to accelerate research timelines and reduce reliance on animal testing. VivoSim Labs also offers custom assay development, contract research services, and collaborative partnerships to address unique project requirements.

Founded to leverage advances in cellular biology and biofabrication, VivoSim Labs has positioned itself as an innovator in the life sciences tools market. Headquartered in the United States, the company serves a global customer base spanning North America, Europe and Asia. With a focus on expanding its product pipeline, scaling manufacturing capabilities and forging strategic alliances, VivoSim Labs aims to enhance the predictability of preclinical studies and drive more efficient drug development pathways.

View VivoSim Labs Profile
Earnings Tools